Neuvivo’s NP001 for Treatment of ALS Slows Disease Progression Through Regulation of Microbial Translocation
Paper Published in ‘Biomedicines’ Highlights MOA, Links Biomarker Changes to Positive Clinical Outcomes
Excerpt from the Press Release:
PALO ALTO Calif., Dec. 1, 2022 /PRNewswire/ — Neuvivo today announced the publication of a peer-reviewed paper titled: “Macrophage Targeted Sodium Chlorite (NP001) Slows Progression of ALS through Regulation of Microbial Translocation”. The goal of the biomarker-focused study was to test the relationship between NP001 macrophage-targeted immune regulation and the theory that microbial translocation contributed to ALS progression.
Published in the journal ‘Biomedicines‘, the peer-reviewed study shows a clear relationship between microbial translocation, inflammation, and disease pathogenesis. Microbial translocation is a process that occurs when bacteria from the gut break through the epithelial barrier and leak into the bloodstream. This initiates a self-perpetuating cycle of inflammation now shown to be directly related to the pathogenesis of ALS and potentially other diseases.
NP001 treatment has been shown to restore the normal process of resolution in the inflammatory cycle and in so doing, restore the integrity of the epithelial barrier in the gut – halting damaging microbial translocation. In this study, the immunoregulatory activity of NP001 treatment has been confirmed via the normalization of key blood biomarkers.
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?